Pulmonx Corporation (LUNG)

Cash-burning single-product medtech with a high and improving 77% gross margin and a genuinely narrowing loss trajectory, but negative operating cash flow in every year of its history, trailing revenue that has turned negative, a 14% effective-rate secured debt facility with an escalating revenue covenant, and heavy ongoing dilution. Net cash of roughly $15 million and no going-concern qualification keep it out of distress, but the fundamentals read weak and inconsistent overall.

The dominant near-term signal is a market-rewarded but trailing Q3 2026 print (earnings, 2026-10-27, announced, partially priced in — revenue +6% to $22.8M, gross margin 76%, net loss down 40%, FY2026 revenue guidance reaffirmed) reinforced by a Stifel price-target raise on a "commercial turnaround" and a Zacks upgrade to Buy, set against a flat sentiment delta (baseline polarity_score ≈ +0.11 on n=3 versus scoring ≈ +0.20 on n=2, inside the ±0.1 flat band, low confidence) and a Red-Flag Screen that is clean, with no severe or moderate flag fired and therefore no cap applied. Because the rewarded catalyst is already eight days old with no forward-dated driver inside 30 days and the structural backdrop remains weak (9M 2026 revenue −2.5% YoY, never-positive operating cash flow, a revenue covenant escalating to $107.5M TTM on 14%-effective secured debt), the read is a genuinely mixed, post-event setup rather than a top-band one.

Price 2.72 (2026-11-03 close) sits above sma20 2.08, sma50 2.07, sma200 1.66, ema9 2.49 and ema21 2.22 — a full bullish MA stack — with RSI14 63.94, MACD line 0.21 above signal 0.10 (histogram 0.11), ADX14 33.87 and rising, and Williams %R -35.33, so trend and momentum both point up. The structure, however, is a violent post-earnings re-rating rather than a clean base: 1.98 on 2026-10-27 to a 3.25 high on 2026-10-29, back to 2.58 on 2026-11-02 (-15.1% distribution day), then 2.72 on 2026-11-03, leaving price roughly 31% above its SMA20 and just under tema14 2.83 while ATR14 is 0.24 (8.82% of price). That is a constructive but extended chart, scored 3 (mixed: bullish trend and momentum versus extension and two heavy distribution sessions). No trade is emitted: fundamentalScore 2 is below the required floor of 3 and the 20-day average dollar volume (~$2.87M) is below the $5M liquidity floor.